Extended Release (ER) Niacin/Laropiprant Add on Study (0524A-082)

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, 12-Week Study to Evaluate the Efficacy and Safety of Extended Release (ER) Niacin/Laropiprant When Added to Ongoing Lipid-Modifying Therapy in Dyslipidemic Patients Deemed Appropriate for Further Lipid Modification.

The purpose of this study is to test the effect of MK0524A (niacin (+) laropiprant) on lowering bad cholesterol and raising good cholesterol.

Inclusion Criteria:

• Patients 18 years of age or older and on a stable dose of lipid therapy

Exclusion Criteria:

• Patients lipid level is outside the recommended range
• Patients that are HIV positive